Please sign in to follow a disease.
Idiopathic inflammatory myopathy
MONDO:0600023Idiopathic form of inflammatory myopathy.
Also known as: idiopathic myositis
182 clinical trials for this condition and its sub-types, 60 tagged with Idiopathic inflammatory myopathy itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Idiopathic inflammatory myopathy
-
Acquired idiopathic inflammatory myopathy 67 trials · 159 incl. sub-types
9 sub-types
- Polymyositis 36 trials · 100 incl. sub-types Sub-types →
- Juvenile idiopathic inflammatory myopathy 2 trials · 42 incl. sub-types Sub-types →
- Antisynthetase syndrome 21 trials
- Immune-mediated necrotizing myopathy 17 trials
- Overlap myositis 2 trials
- Eosinophilic fasciitis 1 trial
- Focal myositis 0 trials
- Idiopathic eosinophilic myositis 0 trials
- Inflammatory myopathy with abundant macrophages 0 trials
Most studied deeper sub-types
-
Gene therapy shot aims to tame autoimmune diseases in early trial
Disease control OngoingThis early-phase study tests a single injection of a gene therapy called V001-BCMA for people with autoimmune diseases like lupus that have not responded to standard treatments. The therapy targets and modifies specific immune cells to reduce disease activity. The main goal is to…
Early phase 1 • Sponsor: Tongji Hospital • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Engineered immune cells take on lupus and other autoimmune diseases
Disease control OngoingThis early-stage trial is testing a new treatment called CC-97540, which uses a patient's own immune cells modified to target and destroy faulty immune cells. It is for people with severe forms of lupus, myositis, scleroderma, or rheumatoid arthritis that have not improved with s…
Phase 1 • Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
New drug shows promise for Long-Term control of rare muscle disease
Disease control By invitation onlyThis study tests the long-term safety of a drug called efgartigimod PH20 SC in adults with active idiopathic inflammatory myopathy, a group of rare muscle diseases. Participants who completed a previous trial will receive the drug as a shot under the skin for up to 51 months. The…
Phase 3 • Sponsor: argenx • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Engineered immune cells take on lupus and scleroderma in early trial
Disease control By invitation onlyThis early-stage trial is testing a new treatment called KITE-363 for people with severe autoimmune diseases like lupus and scleroderma that haven't improved with standard treatments. KITE-363 is a type of cell therapy where a patient's own immune cells are modified in a lab to t…
Phase 1 • Sponsor: Kite, A Gilead Company • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Promising autoimmune therapy trial pulled before it even started
Disease control CancelledThis study was designed to test a new treatment for people with autoimmune diseases like lupus, scleroderma, and myositis. It combined a specially engineered immune cell product (CLBR001) with a targeted antibody drug (SWI019), with or without a preparatory chemotherapy step. How…
Phase 1 • Sponsor: Calibr, a division of Scripps Research • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New hope for myositis: early IVIg may boost recovery
Disease control OngoingThis study tests whether adding intravenous immunoglobulin (IVIg) to standard steroid treatment early in myositis helps patients improve faster. Myositis is a group of rare diseases causing muscle inflammation and weakness. The trial includes 44 adults diagnosed within the past y…
Phase 2/3 • Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Immune system overhaul: could CAR T-Cells tame autoimmune disease?
Disease control OngoingThis early-stage trial is testing a new treatment called KYV-101 for people with severe autoimmune diseases like lupus, scleroderma, and vasculitis. The treatment involves taking a patient's own immune cells, modifying them to target and destroy faulty B cells, and giving them ba…
Phase 1 • Sponsor: David Porter • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Immune cell therapy aimed at autoimmune diseases hits early snag
Disease control CancelledThis early-phase trial planned to test a one-time infusion of genetically modified immune cells (CAR-T cells) targeting CD19 in people with several autoimmune diseases, including lupus and multiple sclerosis. The goal was to see if it was safe and could reduce harmful antibodies.…
Early phase 1 • Sponsor: Nanjing Bioheng Biotech Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC